Trial Profile
Phase 1/2 trial of WT1 Cancer Vaccine in patients with multiple myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Mar 2017
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Sellas Life Sciences Group
- 01 Mar 2017 Updated positive Results published in a Sellas Life Sciences Group media release.
- 13 Oct 2016 Interim results published in the Sellas Life Sciences Media Release
- 15 Jan 2016 New trial record